摘要:
The present invention relates to methods for metabolically loading extracellular vesicles (EVs) with a pharmacological agent. The methods comprise culturing EV source cells in the presence of a metabolic component comprising a pharmacological agent, which is thereby incorporated into the EV-producing cells and subsequently into the EV. The invention further relates to medical uses and compositions of such EVs.
摘要:
The present invention relates to methods and kits for detecting Myo/Nog cells in a sample containing human adipose tissue, as well as therapeutic use thereof for tissue regeneration.
摘要:
This disclosure relates to populations and compositions of purified cell-derived vesicles and uses thereof. One aspect of the disclosure relates to methods for purifying the cell-derived vesicles.
摘要:
The present disclosure provides a genetically modified cell, wherein the cell is genetically modified such that it does not produce functional Ptch1 and Ptch2 protein. The present disclosure provides screening methods to identify agents that modulate the Hedgehog (Hh) pathway. Agents of interest include those that inhibit the Hh pathway response of Ptch1 -/- ; Ptch2 -/- cells, and those that further induce the Hh pathway of these cells.
摘要:
The present application discloses a method for generating human tissues in a non-human animal comprising: (i) generating human naive state stem cells and injecting them into a blastocyst or embryo of a non-human animal such that a chimeric animal is generated; (ii) harvesting human tissues, organs, cells or factors secreted by or made in the human tissues or cells from the chimeric animal; and (iii) transplanting or administering the harvested material into a human resulting in generation of human tissues in a non-human animal.
摘要:
The invention provides methods and compositions relating to molecular targets identified as being capable of increasing or decreasing thermogenic potential in cells, including preadipocytes. Included in the invention are methods and compositions relating to inhibiting or suppressing the activity of an uncoupling protein 1 (UCPl) negative regulator, such as cardiac actin 1 (ACTCl), somatostatin receptor 1 (SSTRl), FAT atypical cadherin 1 (FAT1), and protein tyrosine phosphatase receptor type B (PTPRB). Also included in the invention are methods and compositions relating to activating a UCPl positive regulator, such as phosphatidylinositol-3,4,5,-triphosphate-dependent Rac exchange factor 1 (PREXl), cortactin binding protein 2 (CTTNBP2), doublesex and mab-3-related transcription factor- like family Al (DMRTA1), and endothelin receptor type B (ENDRB). The invention also provides methods and compositions relating to enrichment of cells having thermogenic potential based on cell surface markers, e.g., CD29, identified as being predictive of such.
摘要:
Methods and compositions for producing cells expressing CD56/Pax3, CD56Pax7, and/or Pax3/Pax7 are provided herein. In some instances, the method involves contacting a pluripotent stem cell in an in vitro culture with one compound, or with two or more compounds at the same time, wherein the contacting the pluripotent stem cell in the in vitro culture with one compound, or with two or more compounds at the same time, directly results in generation of cells expressing CD56/Pax3, CD56/Pax7, or Pax3/Pax7. Also provided are methods of using the generated cells. Typically one of the compounds is a wnt pathway activator, such as the GSK3 inhibitor CHIR99021.